The genetics and biology of KRAS in lung cancer

Chinese Journal of Cancer

Volumn 32, Issue 2, 2013, Pages 63-70

  Westcott, Peter M K ^a,c   To, Minh D ^b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

KRAS; Lung cancer; Oncogene; RAS

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR; K RAS PROTEIN; PROTEIN P53; PROTEIN TYROSINE KINASE;

CANCER GENETICS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CODON; GENE MUTATION; GENETIC CONSERVATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MOLECULAR DYNAMICS; NONHUMAN; ONCOGENE K RAS; PALMITOYLATION; PRENYLATION; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN MODIFICATION; PROTEIN MOTIF; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL TRANSFORMATION, NEOPLASTIC; DISEASE SUSCEPTIBILITY; GENE KNOCKDOWN TECHNIQUES; GENETIC THERAPY; HUMANS; LUNG NEOPLASMS; MICE; MUTATION; NEOPLASMS, EXPERIMENTAL; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84873660518     PISSN: 1000467X     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.012.10098     Document Type: Review

References (72)

1. Bos JL. ras oncogenes in human cancer: a review. Cancer Res, 1989,49:4682-4689.
2. Konstantinopoulos PA, Karamouzis MV, Papavassiliou AG. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov, 2007,6:541-555.
3. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J, 1995,9:726-735.
4. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet, 2006,7:606-619.
5. Wolthuis RM, Bos JL. Ras caught in another affair: the exchange factors for Ral. Curr Opin Genet Dev, 1999,9:112-117.
6. Lambert JM, Lambert QT, Reuther GW, et al. Tiam1 mediates Ras activation of Rac by a PI(3)K-independent mechanism. Nat Cell Biol, 2002,4:621-625.
7. Gonzalez-Garcia A, Pritchard CA, Paterson HF, et al. RalGDS is required for tumor formation in a model of skin carcinogenesis. Cancer Cell, 2005,7:219-226.
8. Malliri A, van der Kammen RA, Clark K, et al. Mice deficient in the Rac activator Tiam1 are resistant to Ras-induced skin tumours. Nature, 2002,417:867-871.
9. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin, 2010,60:277-300.
10. Suzuki Y, Orita M, Shiraishi M, et al. Detection of ras gene mutations in human lung cancers by single-st rand conformation polymorphism analysis of polymerase chain reaction products. Oncogene, 1990,5:1037-1043.
11. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature, 2008,455: 1069-1075.
12. Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol, 1999,17:668-675.
13. Nelson MA, Wymer J, Clements N, Jr. Detection of K-ras gene mutations in non-neoplastic lung tissue and lung cancers. Cancer Lett, 1996,103:115-121.
14. Mitsudomi T, Viallet J, Mulshine JL, et al. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene, 1991,6: 1353-1362.
15. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer, 2001,92: 1525-1230.
16. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res, 2011,39:D945-D950.
17. Garassino MC, Marabese M, Rusconi P, et al. Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol, 2011,22: 235-237.
18. Gautschi O, Huegli B, Ziegler A, et al. Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer Lett, 2007,254:265-273.
19. Mascaux C, lannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer, 2005,92:131-139.
20. Sasaki H, Okuda K, Kawano O, et al. Nras and Kras mutation in Japanese lung cancer patients: genotyping analysis using LightCycler. Oncol Rep, 2007,18:623-628.
21. Camps C, Sirera R, Bremnes R, et al. Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? Lung Cancer, 2005,50: 339-346.
22. Keohavong P, DeMichele MA, Melacrinos AC, et al. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res, 1996,2:411-418.
23. Gnanasampanthan G, Elsaleh H, McCaul K, et al. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer. J Pathol, 2001,195: 543-548.
24. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J Clin Oncol, 2007,25:5240-5247.
25. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med, 2005,352:2589-2597.
26. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol, 2005,23:5900-5909.
27. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med, 2005,2:e17.
28. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med, 2009,360:563-572.
29. Johnson L, Greenbaum D, Cichowski K, et al. K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev, 1997,11:2468-2481.
30. Plowman SJ, Williamson DJ, O'Sullivan MJ, et al. While K-ras is essential for mouse development, expression of the K-ras 4A splice variant is dispensable. Mol Cell Biol, 2003,23:9245-9250.
31. Potenza N, Vecchione C, Notte A, et al. Replacement of K-Ras with H-Ras supports normal embryonic development despite inducing cardiovascular pathology in adult mice. EMBO Rep, 2005,6:432-437.
32. To MD, Perez-Losada J, Mao JH, et al. A functional switch from lung cancer resistance to susceptibility at the Pas1 locus in Kras2LA2 mice. Nat Genet, 2006,38:926-930.
33. To MD, Wong CE, Karnezis AN, et al. Kras regulatory elements and exon 4A determine mutation specificity in lung cancer. Nat Genet, 2008,40:1240-1244.
34. You M, Candrian U, Maronpot RR, et al. Activation of the Kiras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci U S A, 1989,86:3070-3074.
35. You M, Wang Y, Lineen AM, et al. Mutagenesis of the K-ras protooncogene in mouse lung tumors induced by N-ethyl-N-nitrosourea or N-nitrosodiethylamine. Carcinogenesis, 1992,13: 1583-1586.
36. Fisher GH, Wellen SL, Klimstra D, et al. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev, 2001,15:3249-3262.
37. Johnson L, Mercer K, Greenbaum D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature, 2001,410:1111-1116.
38. Jackson EL, Willis N, Mercer K, et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev, 2001,15:3243-3248.
39. Yokota J, Kohno T. Molecular footprints of human lung cancer progression. Cancer Sci, 2004,95:197-204.
40. Jackson EL, Olive KP, Tuveson DA, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res, 2005,65:10280-10288.
41. Zhang Z, Wang Y, Vikis HG, et al. Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet, 2001,29:25-33.
42. Sweet-Cordero A, Tseng GC, You H, et al. Comparison of gene expression and DNA copy number changes in a murine model of lung cancer. Genes Chromosomes Cancer, 2006,45: 338-348.
43. To MD, Quigley DA, Mao JH, et al. Progressive genomic instability in the FVB/Kras (LA2) mouse model of lung cancer. Mol Cancer Res, 2011,9:1339-1345.
44. Li J, Zhang Z, Dai Z, et al. LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer. Oncogene, 2003,22:1243-1246.
45. Gariboldi M, Manenti G, Canzian F, et al. A major susceptibility locus to murine lung carcinogenesis maps on chromosome 6. Nat Genet, 1993,3:132-136.
46. You M, Wang Y, Stoner G, et al. Parental bias of Ki-ras oncogenes detected in lung tumors from mouse hybrids. Proc Natl Acad Sci U S A, 1992,89:5804-5808.
47. Chin LJ, Ratner E, Leng S, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res, 2008, 68:8535-8540.
48. Kohno T, Kunitoh H, Suzuki K, et al. Association of KRAS polymorphisms with risk for lung adenocarcinoma accompanied by atypical adenomatous hyperplasias. Carcinogenesis, 2008,29:957-963.
49. Manenti G, De Gregorio L, Pilotti S, et al. Association of chromosome 12p genetic polymorphisms with lung adenocarcinoma risk and prognosis. Carcinogenesis, 1997,18:19171920.
50. Dragani TA, Hirohashi S, Juji T, et al. Population-based mapping of pulmonary adenoma susceptibility 1 locus. Cancer Res, 2000,60:5017-5020.
51. Manenti G, Nomoto T, De Gregorio L, et al. Predisposition to lung tumorigenesis. Toxicol Lett, 2000,112-113:257-263.
52. Patek CE, Arends MJ, Wallace WA, et al. Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis. Exp Cell Res, 2008,314:1105-1114.
53. Pells S, Divjak M, Romanowski P, et al. Developmentally-regulated expression of murine K-ras isoforms. Oncogene, 1997,15:1781-1786.
54. Wang Y, You M, Wang Y. Alternative splicing of the K-ras gene in mouse tissues and cell lines. Exp Lung Res, 2001,27: 255-267.
55. Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell, 2005,121:823-835.
56. Xu X, Rock JR, Lu Y, et al. Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma. Proc Natl Acad Sci U S A, 2012,109:4910-4915.
57. Fiordalisi JJ, Johnson RL 2nd, Weinbaum CA, et al. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltrans-ferase inhibitors. J Biol Chem, 2003,278:41718-41727.
58. Lobell RB, Omer CA, Abrams MT, et al. Evaluation of farnesyl: protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res, 2001,61:8758-8768.
59. Lobell RB, Liu D, Buser CA, et al. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. Mol Cancer Ther, 2002,1:747-758.
60. Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell, 2009,15:489-500.
61. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature, 2010,464:1067-1070.
62. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature, 2002,417:949-954.
63. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature, 2010,464:431-435.
64. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell, 2010,140:209-221.
65. Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature, 2010,464:427-430.
66. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med, 2012,366:207-215.
67. Blasco RB, Francoz S, Santamaria D, et al. c-Raf, but not B-Raf, is essential for development of K-Ras oncogene-driven non-small cell lung carcinoma. Cancer Cell, 2011,19:652-663.
68. Kaelin WG, Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer, 2005,5:689-698.
69. Puyol M, Martin A, Dubus P, et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell, 2010,18:63-73.
70. Barbie DA, Tamayo P, Boehm JS, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature, 2009,462:108-112.
71. Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell, 2009,137:835-848.
72. Scholl C, Frohling S, Dunn IF, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell, 2009,137:821-834.